Search

Your search keyword '"Eagle Pharmaceuticals Inc. -- Intellectual property"' showing total 83 results
Start Over Descriptor "Eagle Pharmaceuticals Inc. -- Intellectual property"
83 results on '"Eagle Pharmaceuticals Inc. -- Intellectual property"'

1. Patent Issued for Fulvestrant formulations and methods of their use (USPTO 11590077)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Women -- Health aspects, Fulvestrant -- Intellectual property -- Methods, Health, Women's issues/gender studies, Faslodex (Medication) -- Intellectual property
Abstract

2023 MAR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent by the inventors Chen, Feng-Jing (Irvine, CA, US), Hepner, Adrian (Ramsey, NJ, [...]

Published
2023

2. Eagle Pharmaceuticals Granted Patent for PEMFEXY(R)

Subjects
United States. Securities and Exchange Commission, United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Banking, finance and accounting industries, Business, Pemfexy (Medication) -- Intellectual property
Abstract

WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that the U.S. Patent and Trademark Office has granted the [...]

Published
2023

3. Eagle Pharmaceuticals secures key patent for PEMFEXY in US market

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Chemistry, Pemfexy (Medication) -- Intellectual property
Abstract

M2 PHARMA-October 24, 2023-Eagle Pharmaceuticals secures key patent for PEMFEXY in US market (C)2023 M2 COMMUNICATIONS US pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) announced on Tuesday that the US Patent [...]

Published
2023

4. Eagle Pharmaceuticals secures key patent for PEMFEXY in US market

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Pemetrexed -- Intellectual property, Drug approval, Business, Pemfexy (Medication) -- Intellectual property
Abstract

M2 EQUITYBITES-October 24, 2023-Eagle Pharmaceuticals secures key patent for PEMFEXY in US market (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk US pharmaceutical company Eagle Pharmaceuticals Inc (Nasdaq:EGRX) announced on Tuesday that the US [...]

Published
2023

5. Researchers Submit Patent Application, 'Methods Of Using Dantrolene To Treat Nerve Agent Exposure', for Approval (USPTO 20200383954)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Central nervous system depressants -- Methods -- Intellectual property, Povidone -- Methods -- Intellectual property, Nerve gas -- Methods -- Intellectual property, Physical fitness -- Methods, Health
Abstract

2021 JAN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2021

6. Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA(R) (bendamustine hydrochloride)

Subjects
United States. Federal Trade Commission, United States. Department of Justice, Eagle Pharmaceuticals Inc. -- Intellectual property, Hospira Inc. -- Intellectual property, Bendamustine, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business
Abstract

WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that it has reached a settlement agreement with Accord Healthcare, [...]

Published
2022

7. 'Fulvestrant Formulations' in Patent Application Approval Process (USPTO 20200188411)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patient compliance, Fulvestrant -- Intellectual property, Health
Abstract

2020 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent application by the inventor Palepu, Nageswara R. (Southampton, PA), filed [...]

Published
2020

8. Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA(R) (bendamustine hydrochloride) until January 17, 2028

Subjects
Apotex Inc. -- Intellectual property, Eagle Pharmaceuticals Inc. -- Intellectual property, Hospira Inc. -- Intellectual property, Patents, Bendamustine, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Banking, finance and accounting industries, Business
Abstract

WOODCLIFF LAKE, Apr 19, 2022 (GLOBE NEWSWIRE via COMTEX) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that it has reached a settlement agreement with Hospira, [...]

Published
2022

10. Eagle Pharmaceuticals Wins Vasopressin Patent Trial

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Business, international, Law
Abstract

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that the U.S. District Court for the District of Delaware held that Eagles proposed vasopressin product does not infringe [...]

Published
2021

11. Eagle Pharmaceuticals Wins Vasopressin Patent Trial

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or the 'Company') today announced that the U.S. District Court for the District of Delaware held that Eagle's proposed vasopressin [...]

Published
2021

12. Eagle Pharmaceuticals receives new US patent for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Pharmaceuticals and cosmetics industries
Abstract

Byline: Woodcliff Lake Eagle Pharmaceuticals, Inc. announced that an additional patent has been issued related to Bendeka by the United States Patent and Trademark Office (USPTO). Patent number 10,010,533 will [...]

Published
2018

13. Endo International gets Paragraph IV notification on Vasostrict

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Generic drugs, Pharmaceutical industry -- Intellectual property, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April 16, 2018 advising that Eagle Pharmaceuticals, Inc. (Eagle) [...]

Published
2018

14. Court's Drug Patent Prescription: Unclaimed Disclosure Is Dedicated

Subjects
United States. Court of Appeals for the Federal Circuit, Eagle Pharmaceuticals Inc. -- Intellectual property, Generic drugs -- Intellectual property, Patent infringement, Bendamustine, Lymphocytic leukemia, Lymphomas, Disclosure of information, Chronic lymphocytic leukemia, Non-Hodgkin's lymphomas, Tumors, Business, international
Abstract

Addressing the disclosure-dedication doctrine, the US Court of Appeals for the Federal Circuit concluded that the disclosure-dedication doctrine barred a patent owner's claim of infringement under the doctrine of equivalents [...]

Published
2020

16. Patent Issued for Formulations of Bendamustine (USPTO 9597399)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- EAGLE PHARMACEUTICALS, INC. (Woodcliff Lakes, NJ) has been issued patent number 9597399, [...]

Published
2017

17. Patent Issued for Formulations of Bendamustine (USPTO 9597398)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a [...]

Published
2017

18. Patent Issued for Formulations of Bendamustine (USPTO 9597397)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Alexandria, Virginia, NewsRx journalists report that a patent by the inventor [...]

Published
2017

19. Patent Issued for Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration (USPTO 9579384)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness -- Methods, Patents -- Methods, Antineoplastic agents -- Methods, Patent/copyright issue, Health
Abstract

2017 MAR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A patent by the inventors Sundaram, Srikanth (Somerset, NJ); Tarriff, Scott L. [...]

Published
2017

20. Patent Issued for Formulations of Bendamustine (USPTO 9572888)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ) has been issued patent number 9572888, [...]

Published
2017

21. Patent Issued for Formulations of Bendamustine (USPTO 9572887)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a [...]

Published
2017

22. Patent Issued for Formulations of Bendamustine (USPTO 9572797)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ) has been issued patent number 9572797, [...]

Published
2017

23. Patent Issued for Formulations of Bendamustine (USPTO 9572796)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Physical fitness, Patents, Antineoplastic agents, Patent/copyright issue, Health
Abstract

2017 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a [...]

Published
2017

27. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA (Updated on 22-08-2018)

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

WOODCLIFF LAKE: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that an additional patent has been issued related [...]

Published
2018

28. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Business, Business, international
Abstract

- BENDEKA protected by 16 patents running from 2026 through 2033 - - Fifteen total Orange Book listed patents - WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' [...]

Published
2018

29. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

WOODCLIFF LAKE, N.J: Eagle Pharmaceuticals, Inc. has issued the following press release: -Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or 'the Company') today announced that an additional patent has been issued related [...]

Published
2018

30. Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business, Business, international
Abstract

-- BENDEKA protected by 15 patents running from 2026 through 2033 - -- Fourteen total Orange Book listed patents -- WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or [...]

Published
2018

31. Endo Receives Paragraph IV Notification on Vasostrict

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Generic drugs, Drug approval, Pharmaceutical industry -- Intellectual property, Business, News, opinion and commentary
Abstract

DUBLIN, April 17, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated [...]

Published
2018

32. Eagle Pharmaceuticals Announces New Patent for Eagle Biologics

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Biological products, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

WOODCLIFF LAKE: Eagle Pharmaceuticals, Inc has issued the following press release: -Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company's Eagle Biologics division has been [...]

Published
2018

33. Eagle Pharmaceuticals Announces New Patent for Eagle Biologics

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Biological products, Patent/copyright issue, Business, Business, international
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company's Eagle Biologics division has been issued a new patent by the United [...]

Published
2018

34. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary, Ryanodex (Medication)
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: -Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a new [...]

Published
2018

35. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary, Ryanodex (Medication)
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a new [...]

Published
2018

36. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary, Ryanodex (Medication)
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a new [...]

Published
2018

37. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary, Ryanodex (Medication)
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a new [...]

Published
2018

38. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary, Ryanodex (Medication)
Abstract

WOODCLIFF LAKE, N.J: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a [...]

Published
2018

39. Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent for RYANODEX

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Dantrolene, Patents, Drug approval, Patent/copyright issue, Business, Business, international, Ryanodex (Medication)
Abstract

WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ('Eagle' or 'the Company') today announced that the Company has been issued a new patent related to its RYANODEX([R]) product (dantrolene [...]

Published
2018

41. Patent Application Titled 'Formulations Of Bendamustine' Published Online (USPTO 20190192659)

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Leukemia, Bendamustine, Antineoplastic agents, Editors, Business, Health, Health care industry
Abstract

2019 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

42. Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Business, Business, international, Ryanodex (Medication)
Abstract

-- Bendeka market share of 97% with record royalty revenue of $41.4 million -- -- Revenue grows 67% year-over-year to $63.0 million -- -- New patent related to RYANODEX granted [...]

Published
2017

43. Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or 'the Company') today announced that three additional patents have been issued related to [...]

Published
2017

44. Eagle Pharmaceuticals awarded three new patents in the US for Bendeka

Subjects
United States. Food and Drug Administration, Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Mar 22, 2017 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Eagle Pharmaceuticals Inc (NasdaqGM:EGRX) revealed on Tuesday the receipt of three additional patents protecting Bendeka from the US Patent and [...]

Published
2017

45. Eagle Pharmaceuticals awarded 11th US patent for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Mar 01, 2017 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Eagle Pharmaceuticals Inc (NYSE:EGRX) reported on Tuesday that it has received its 11th US patent for Bendeka from the US [...]

Published
2017

46. United States : Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business, international
Abstract

Eagle Pharmaceuticals, Inc. (Eagle or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued an 11th patent related to Bendeka. Patent number 9,579,384 will [...]

Published
2017

47. Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business, Business, international
Abstract

Bendeka protected by 11 patents running from 2026 through 2033 Ten Orange Book listed patents WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or 'the Company') today announced that [...]

Published
2017

48. Eagle Pharmaceuticals Announces New Patents Issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, General interest, News, opinion and commentary
Abstract

Woodcliff Lake: Eagle Pharmaceuticals, Inc. has issued the following press release: -Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ('Eagle' or 'the Company') today announced that four additional patents have been issued related to [...]

Published
2017

49. United States : Eagle Pharmaceuticals announces new patents issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Drug approval, Patent/copyright issue, Business, international
Abstract

Eagle Pharmaceuticals, Inc. (Eagle or the Company) today announced that four additional patents have been issued related to Bendeka by the United States Patent and Trademark Office (USPTO). Patent numbers [...]

Published
2017

50. Eagle Pharmaceuticals Announces New Patents Issued for Bendeka

Subjects
Eagle Pharmaceuticals Inc. -- Intellectual property, Patents, Patent/copyright issue, Business, Business, international
Abstract

-- Bendeka protected by 10 patents running from 2026 through 2033 - -- Total of nine Orange Book listed patents - -- Additional four patents allowed -- WOODCLIFF LAKE, N.J. [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results